PET/CT in Head and Neck Tumours

  • Wai Lup WongEmail author
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)


FDG PET/CT has an established role in the assessment of head and neck squamous cell cancer (H&N SqCC). As such, the focus of the chapter will be on FDG PET/CT and H&N SqCC. Separate short commentaries are provided on the role of FDG PET/CT for other tumours and on the evolving role of radio-tracers beyond FDG. Specific comments relevant to H&N haematolymphoid disorders is included in the appendix.


  1. 1.
    Wong WL, Ross P, Corcoran M. Evidence based guidelines recommendations on the use of PET CT imaging in head and neck cancer from Ontario and guidelines in general- some observations. Clin Oncol. 2013;25:242–5.CrossRefGoogle Scholar
  2. 2.
    Dong MJ, Zhao K, Lin XT, Zhao J, Ruan LX, Liu ZF. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature. Nucl Med Commun. 2008;29(9):791–802.PubMedGoogle Scholar
  3. 3.
    Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer. 2004;101:2641–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Wong WL, Sonoda LI, Gharpurhy A, Gollub F, Wellsted D, Goodchild K, Lemon C, Farrell R, Saunders M. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of occult primary head and neck cancers--an audit and review of published studies. Clin Oncol. 2012;24:190–5.CrossRefGoogle Scholar
  5. 5.
    Cancer of the upper aero-digestive tract tumours: assessment and management in people aged 16 and over. NICE guideline 36. February 2016.Google Scholar
  6. 6.
    Haerle SK, Schmidt DT, Ahmad N, Hany TF, Stoeckli SJ. The value of f-18-FDG PET/CT for the detection of distant metastases in high risk patients with head and neck squamous cell carcinoma. Oral Oncol. 2011;47:653–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Ng SH, Chan SC, Liao CT, Chang JT, Koo SF, Wang HM, Chin SC, Lin CY, Huang SF, Yen TC. Distant metastases and synchronous second primary tumours in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18) F-FDG and extended field multi-detector row CT. Neuroradiology. 2008;50:969–79.CrossRefPubMedGoogle Scholar
  8. 8.
    Liu FY, Lin CY, Chang JT, Ng SH, Chin SC, Wang HM, Liao CT, Chan SC, Yen T. [18]F FDG PET can replace conventional workup in primary M staging of non keratinizing nasopharyngeal carcinoma. J Nucl Med. 2007;48:1614–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Abgal R, Le Roux P-Y, Keromnes N, et al. Early prediction of survival following induction chemotherapy with DCF using FDG PET/CT imaging in patients with locally advanced head and neck cancer. Eur J Nucl Med Mol Imaging. 2012;39:1839–47.CrossRefGoogle Scholar
  10. 10.
    Isles MG, McConkey MG, Mehanna HM. A systematic review and metaanalysis of the role of PET in the follow-up of head and neck cancer following radiotherapy and chemotherapy. Clin Otolaryngol. 2008;33:210–22.CrossRefPubMedGoogle Scholar
  11. 11.
    Abgral R, Querellou S, Potand G, Le-Roux P-Y, Le Du-Pennec A, Marianovski R, Pradier O, Bazais Y, Kraeber-Bodere F, Saluun PY. Does FDG PET CT improve the detection of post treatment recurrence of head and neck carcinoma in patients negative for disease on clinical follow up. J Nucl Med. 2009;50:24–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Porceddu SV, Jarmolowski E, Hicks RJ, Ware R, Weih L, Rishcin D, Corry J, Peters LJ. Utility of PET for the detection of disease in residual neck nodes after [chemo]radiotherapy in head and neck cancer. Head Neck. 2005;27:175.CrossRefPubMedGoogle Scholar
  13. 13.
    Wang Y-F, Liu R-S, Chu P-Y, Chang F-C, Tai S-K, Tsai T-L, Chang S-Y. PET in surveillance of head and neck squamous cell carcinoma after definitive chemoradiotherapy. Head Neck. 2009;31(4):442–51.CrossRefPubMedGoogle Scholar
  14. 14.
    Yao M, Smith RB, Graham MM, Hoffman HT, Tan H, Funk GF, Graham SM, Chang K, Dornfeld KJ, Menda Y, Buatti JM. The role of FDG PET in the management of neck metastasis from head and neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2005;63:991–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Rogers JW, Greven KM, McGuirt WF, Keyes JW, Williams DW II, Watson NE, Geissinger K, Capellari JO. Can post-RT neck dissection be omitted for patients with head and neck cancer who have an a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys. 2004;58:694–7. also see letter in same journal in response to Yao et al by Greven KM 58:307CrossRefPubMedGoogle Scholar
  16. 16.
    Nishumura G, Matsuda H, Taguchi T, Takahashi M, Komatsu M, Sano D, Sakuma N, Arai Y, Takahashi H. Treatment evaluation of metastatic lymph nodes after concurrent chemoradiotherapy in patients with head and neck squamous cell carcinoma. Anticancer Res. 2012;32:595–60.Google Scholar
  17. 17.
    Loo SW, Geropantas K, Beadsmore C, Montgomery PQ, Martin WM, Roques TW. Neck dissection can be avoided after sequential chemo-radiotherapy and negative post treatment PET CT in N2 head and neck cancer. Clin Oncol. 2011;23:512–7.CrossRefGoogle Scholar
  18. 18.
    Mehanna H, Wong W, McConkey CC, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med. 2016;374:1444–54.CrossRefPubMedGoogle Scholar
  19. 19.
    Greven KM. PET for head and neck cancer. Semin Radiat Oncol. 2004;14:121–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Schroder H, Yeung HWD, Gonen M, Kraus D, Larson SM. Head and neck: clinical usefulness and accuracy of PET CT image fusion. Radiology. 2004;231:65.CrossRefGoogle Scholar
  21. 21.
    Troost EGC, Schinagl DAX, Bussinka J, Oyen WJG, Kaanders JHAM. Clinical evidence on PET CT for radiation planning in head and neck tumours. Radiother Oncol. 2010;96:328–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Wong WL, Gibson D, Sanghera B, Goodchild K, Saunders M. Evaluation of normal FDG uptake in palatine tonsil and its potential value for detecting occult head and neck cancers: a PET CT study. Nucl Med Commun. 2007;28:675–80.CrossRefPubMedGoogle Scholar
  23. 23.
    Hoshikawa H, Nishiyama Y, Kishino T, Yamamoto Y, Haba R, Mori N. Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell cancers. Mol Imaging Biol. 2011;13:1172–7.CrossRefGoogle Scholar
  24. 24.
    Troost EG, Vogel WV, Merkx MA, Slootweg PJ, Marres HA, Peeters WJ, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726–35.CrossRefPubMedGoogle Scholar
  25. 25.
    Hoshikawa H, et al. The value of 18F-FLT for detecting second primary cancers and distant metastases in head and neck cancer. Clin Nucl Med. 2013;38:318–24.CrossRefGoogle Scholar
  26. 26.
    Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med. 2010;51:866–74.CrossRefPubMedGoogle Scholar
  27. 27.
    Hoeben BA, Troost EG, Span PN, van Herpen CM, Bussink J, Oyen WJ, et al. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med. 2013;54:532–40.CrossRefPubMedGoogle Scholar
  28. 28.
    Kishino T, Hoshikawa H, Nishiyama Y, Yamamoto Y, Mori N. Usefulness of 3′-deoxy-3′-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med. 2012;53:1521–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Chang JH, Wada M, Anderson NJ, et al. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study. Acta Oncol. 2013;52:1723–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Bollineni VR, Koole MJ, Pruim J, et al. Dynamics of tumor hypoxia assessed by (18)F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Radiother Oncol. 2014;113:198–203.CrossRefPubMedGoogle Scholar
  31. 31.
    Horsman MR, Motensen LS, Peterson BM, Overgaard J. Imaging hypoxia to improve RT outcomes. Nat Rev Clin Oncol. 2012;9:674–87.CrossRefPubMedGoogle Scholar
  32. 32.
    Carlin S, Humm JL. PET of hypoxia: current and future perspectives. J Nucl Med. 2012;53:1171.CrossRefPubMedGoogle Scholar
  33. 33.
    Wu HB, Wang QS, Wang MF, Zhen X, Zhou W-I, Li H-S. Preliminary study of 11C-choline PET/CT for T staging of locally advanced nasopharyngeal carcinoma: comparison with 18F-FDGH PET/CT. J Nucl Med. 2011;52:341–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Ito K, Kubota K, Morooka M, Yokoyama J. Comparison of PET CT with F18-FDG and with C11-choline for the detection of recurrence of head and neck cancer after radiotherapy. J Nucl Med. 2009;50(suppl 2):1780.Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Paul Strickland Scanner Centre, Department of Nuclear MedicineMount Vernon HospitalNorthwoodUK

Personalised recommendations